Wave Life Sciences Ltd.
NASDAQ:WVEBiotechnology
Healthcare
$2.72 +1.63%
+$0.10 today
- Market cap
- $536.46M
- Beta
- -1.33
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$0.92
52W Low $5.02High $21.73
Volume 1.92M
Average 4.86M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$187.49M
FY 2025 · Annual
Investing Cash Flow
-$718,000.00
FY 2025 · Annual
Financing Cash Flow
$488.24M
FY 2025 · Annual
+92.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (122.25M) | (161.82M) | (57.51M) | (97.01M) | (204.38M) |
| Depreciation & Amortization | 9.84M | 10.11M | 9.21M | 8.66M | 8.85M |
| Deferred Income Tax | (12.64M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.41M | 17.19M | 9.8M | 13.14M | 0 |
| Change in Working Capital | 7.01M | 6.72M | 19.08M | (75.82M) | (16.94M) |
| Accounts Receivables | 30M | 0 | (21.09M) | 19.66M | 146K |
| Inventory | 2.04M | 0 | 0 | 0 | 0 |
| Accounts Payables | (6.57M) | 9.35M | (3.76M) | 3.42M | (561K) |
| Other Working Capital | (18.46M) | (2.63M) | 43.93M | (98.91M) | (16.53M) |
| Other Non-Cash Items | 12.64M | 12K | 0 | 0 | 24.97M |
| Operating Cash Flow | (88.99M) | (127.78M) | (19.43M) | (151.03M) | (187.49M) |
| Capital Expenditures | (560K) | (1.36M) | (1.12M) | (938K) | (718K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (75.04M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 75.04M | 0 | 0 | 0 |
| Other Investing Activities | 0 | 106K | 0 | 0 | 0 |
| Investing Cash Flow | (560K) | (1.26M) | (1.12M) | (938K) | (718K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 54.97M | 52.33M | 131.28M | 236.18M | 488.24M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 858K | 14.86M | 1.26M | 17.71M | 0 |
| Financing Cash Flow | 55.83M | 67.19M | 132.53M | 253.89M | 488.24M |
| Effect of Forex Changes | (208K) | (210K) | (95K) | (138K) | 12K |
| Net Change in Cash | (33.93M) | (62.06M) | 111.89M | 101.79M | 300.04M |
| Free Cash Flow | (89.55M) | (129.14M) | (20.55M) | (151.96M) | (187.49M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$204.4M
+ D&A$8.9M
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$16.9M
+ Other Non-Cash$25.0M
= Operating Cash Flow-$187.5M
- Capex-$718.0K
= Free Cash Flow-$187.5M
Analysis
FY2025 free cash flow is -$187.5M. FCF conversion is 91.7% of net income. Operating cash flow was -$187.5M, with capex of -$718.0K. The largest bridge item is Other Non-Cash at $25.0M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Oct 27, 2026 | |
| 8-K | Current report | Oct 27, 2026 | |
| 10-Q | Quarterly report | Oct 27, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| ARS | ARS filing | Oct 14, 2026 |
Does WVE generate free cash flow?
Wave Life Sciences Ltd. (WVE) generated -$187.49M of free cash flow in fiscal 2025.
How much operating cash flow does WVE produce?
Operating cash flow was -$187.49M, before capital expenditures of $718,000.00.
Continue the stock analysis
Jump to another research area for this company.